ClinicalTrials.gg

Program

GEN-1

Also written as “IMNN-001” and “IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)”.

Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms, led by Imunon.

Furthest: phase 3, since Apr 1, 20254 company-led studies, 3 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Imunon43 open or runningphase 3since Apr 1, 2025Jun 22, 2015Jun 30, 2027phase 2 · NCT05739981

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2015First study: phase 1 study in Carcinoma, Ovarian EpithelialFirst studyNCT02480374 · 18 enrolled · United States
  2. Jan 3, 2018Phase 2 study in Carcinoma, Ovarian EpithelialNCT03393884 · 130 enrolled · United States, Canada
  3. Feb 13, 2023Phase 2 study in Ovarian NeoplasmsNCT05739981 · 30 planned · United States
  4. Apr 1, 2025Phase 3 study in Carcinoma, Ovarian EpithelialNCT06915025 · 500 planned · United States

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT05739981
  2. Oct 31, 2032Primary completion: phase 3 study in Carcinoma, Ovarian EpithelialNCT06915025

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06915025Carcinoma, Ovarian Epithelial · United States3RecruitingOct 31, 2032500
NCT05739981Ovarian Neoplasms · United States2RecruitingJun 30, 202730
NCT03393884Carcinoma, Ovarian Epithelial · United States, Canada2Active, not recruitingJul 25, 2024130
NCT02480374Carcinoma, Ovarian Epithelial · United States1CompletedMay 201718

How it is read

Names in the registry

  • “IMNN-001”, 3 entries
  • “IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.